- Home
- MRCC vs ELTX Comparison
MRCC vs ELTX Comparison
Compare MRCC & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MRCC | ELTX |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.8M | 134.1M |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | MRCC | ELTX |
|---|---|---|
| Price | $6.28 | $7.81 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $8.00 | ★ $13.00 |
| AVG Volume (30 Days) | 84.2K | ★ 110.3K |
| Earning Date | 02-27-2026 | 11-13-2025 |
| Dividend Yield | ★ 11.29% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $43,742,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.86 | $4.60 |
| 52 Week High | $8.85 | $12.62 |
Technical Indicators
Market Signals| Indicator | MRCC | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.89 | 44.71 |
| Support Level | $6.30 | $7.37 |
| Resistance Level | $6.53 | $8.70 |
| Average True Range (ATR) | 0.18 | 0.54 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 12.04 | 23.31 |
Price Performance
Historical ComparisonAbout MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.